Form 4: ForGrowth NAP B.V. Sells Shares of NewAmsterdam Pharma Co N.V. (NAMS)

ForGrowth NAP B.V., a significant shareholder of NewAmsterdam Pharma Co N.V., executed multiple sales of ordinary shares between December 18 and December 19, 2024, under a pre-arranged trading plan.

Summary

• ForGrowth NAP B.V., along with affiliated entities including Forbion Capital Fund IV Cooperatief U.A. and Forbion Growth Opportunities Fund I Cooperatief U.A., sold shares of NewAmsterdam Pharma Co N.V. (NAMS) between December 18 and 19, 2024.
• The sales were conducted under a Rule 10b5-1 trading plan adopted by NAP PoolCo B.V. on March 28, 2024.
• On December 18, 2024, 54,518 ordinary shares were sold at a weighted average price of $25.7172, and another 46,210 shares were sold at a weighted average price of $26.5496.
• On December 19, 2024, 56,506 ordinary shares were sold at a weighted average price of $25.4452.
• The transactions resulted in a decrease in the number of shares beneficially owned by ForGrowth NAP B.V., from 10,954,712 to 10,851,996 ordinary shares.
• The shares are held directly and indirectly through NAP PoolCo B.V., with beneficial ownership split between Forbion Growth Opportunities Fund I Cooperatief U.A. and Forbion Capital Fund IV Cooperatief U.A.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the transactions were pre-planned under a Rule 10b5-1 trading plan. The market reaction will depend on the interpretation of these sales by investors.

Risks

• The continued selling of shares by major shareholders like ForGrowth NAP B.V. could exert downward pressure on the stock price of NewAmsterdam Pharma Co N.V.

Industry Context

Sales by significant shareholders are common, but the market will often scrutinize the reasons behind the sales, especially in the biopharmaceutical industry where stock performance is closely tied to clinical trial outcomes and regulatory approvals. These sales could be part of a planned diversification strategy by the funds or could reflect a change in their outlook for the company.

Comparison to Industry Standards

• Share sales by major shareholders are a common occurrence in the pharmaceutical industry.
• Comparable companies such as Madrigal Pharmaceuticals and Viking Therapeutics often see similar transactions by their institutional investors.
• The impact of these sales on the stock price depends on the size of the transaction relative to the company's market capitalization and the overall market sentiment.

Stakeholder Impact

• Shareholders may react to the news of share sales by a major shareholder, potentially leading to price volatility.
• Employees may be concerned about the long-term implications of these sales, although the pre-planned nature of the transactions mitigates some of this concern.

Key Dates